@article{532062d9673f45a0b526442723affc17,
title = "Minimum Technical Requirements for Performing Ambulatory EEG",
abstract = "Summary:Ambulatory EEG (AEEG) devices offer portable, multichannel, digital EEG recording with or without video in the patient's natural environment. The technology applied for AEEG recording is like the technology for routine EEG and inpatient long-term video-EEG monitoring but designed to be compact and wearable. Computer-based AEEG technology is well-suited to digital recording, signal processing, and visual display. However, acquiring interpretable EEG outside of the hospital setting presents its own technical challenges. Published guidelines have established technical standards for performing routine EEG and inpatient video-EEG monitoring, but technical standards for AEEG are lacking. Therefore, this guideline provides minimal technical standards for the performance of AEEG which are essential to ensure the quality of studies for clinical and research practice. We expect these minimum standards to evolve over time with improved performance and advances in the technology.",
keywords = "Ambulatory, EEG, Guideline, Technical, Video",
author = "Tatum, {William O.} and Halford, {Jonathan J.} and Piotr Olejniczak and Olga Selioutski and Grigg-Damberger, {Madeleine M.} and David Gloss and Jayant Acharya and Stephan Schuele and Sinha, {Saurabh R.} and Tammy Tsuchida and Drislane, {Frank W.}",
note = "Funding Information: W. O. Tatum has received personal compensation in the form of a stipend from Elsevier as Editor-in-Chief of Epilepsy Behavior Reports. He is a consultant for BioSerenity/DigiTrace Care Services, Inc, Zimmer Biomet, Neurelis, and Medtronic. He holds patents or patents pending (#62527896; #62770362) for intraoperative monitoring sensing devices. Royalties from books published on EEG and ambulatory EEG received from Demos Publishers Inc and Springer Publishing. Honoraria for speaking engagements received from the American Academy of Neurology, American Epilepsy Society, and American Clinical Neurophysiology Society. He has received research support from Mayo Clinic, Epilepsy Foundation, Esai, Engage, Xenon, Cerevel Therapeutics, LivaNova, UCB pharma, and the Martin Family Foundation and Lucius B and Terrie McElvey Fund. J. J. Halford serves as a consultant for Takeda Pharmaceuticals and SK Life Sciences. He receives research support from Veterans Affairs Research and Development, Greenwich Biosciences, Takeda Pharmaceuticals, SK Life Sciences, Biogen, Cerevel Therapeutics, and Marinus Pharmaceuticals. P. Olejniczak received honoraria for speaking engagements with UCB Pharma. O. Selioutski received support from SAGE Therapeutics, Sepracor/Sunovion, USL261 for being a primary investigator in industry sponsored clinical trial, and from the University of Rochester CTSI Award Number 3191 from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) and royalties from LWW publishers and UpToDate. M. M. Grigg-Damberger: royalties from UpToDate and Oxford University Press. D. Gloss: no relevant relationships. J. Acharya: no relevant relationships. S. Schuele received personal compensation in form of a stipend from Wolters Kluwer as Associate Editor of the Journal of Clinical Neurophysiology. He receives royalties from a book published from Demos Publishers Inc, Springer Publishing on Stereoencephalography. Honoraria for speaking engagements received from the American Academy of Neurology, American Epilepsy Society, American Clinical Neurophysiology Society, Sunovion Inc, SK Life Science, Neurelis, and Greenwich. T. Tsuchida serves as a consultant for Xenon Pharmaceuticals, grant for investigator-initiated study, and consultant for Hikma Pharmaceuticals. F. W. Drislane received royalties from UpToDate and LWW publishers and honoraria for speaking from the American Academy of Neurology (in 2019). S. R. Sinha received royalties from a book published by Springer publishing; research support from Eisai Inc, Monteris Medical, Neuropace Inc, SAGE Therapeutics, and UCB Pharmaceuticals; personal compensation for advisory boards from Acquestive Therapeutics, LivaNova, Monteris Medical, SK Life Science, and UCB Inc; and consulting for BlackThorn Therapeutics and Basilea Pharmaceutica. Publisher Copyright: {\textcopyright} 2022 Wolters Kluwer Health, Inc. All rights reserved. ",
year = "2022",
month = sep,
day = "1",
doi = "10.1097/WNP.0000000000000950",
language = "English (US)",
volume = "39",
pages = "435--440",
journal = "Journal of Clinical Neurophysiology",
issn = "0736-0258",
publisher = "Lippincott Williams and Wilkins",
number = "6",
}